NRx Pharma secures $27M financing for subsidiary Hope Therapeutics clinic rollup

NRX Pharmaceuticals, Inc.

Private placement of 732,600 shares at $2.73/share for $2M immediate funding.
Investor committed to $25M in Hope Series A Preferred convertible into 1/3 equity, 15% dividend, non-callable for 2 years.
First $6.75M tranche of Hope investment due by Feb 7, 2025; remaining $18.25M by Apr 1, 2025.
Funds to acquire Kadima Neuropsychiatry and start nationwide interventional psychiatry clinic rollup.
Company anticipates pro-forma revenue of ~$100M by end of 2025 using bank leverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.